Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087
Robert Chen, Phillippe Armand, Michelle A Fanale, Vincent Ribrag, Pier Luigi Zinzani, Alejandro D Ricart, Seth Thompson, Arun Balakumaran, Daniel Molin, Margaret A Shipp, Craig H Moskowitz
Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P146; DOI: 10.1186/2051-1426-3-S2-P146